title: Potential for tumor therapy with iodine-125 labeled immunoglobulins.
abstract: Because of the high intranuclear toxicity of Auger-electron emitters, the use of radioiodinated (123I, 125I) 5-iodo-2'-deoxyuridine (IUdR)-antibody conjugates for cancer therapy has been examined. The results have demonstrated that all the conditions necessary for labeling DNA in vivo are present: uptake of the radiolabeled immunoglobulin by target cells, its subsequent internalization, the degradation of the IUdR-protein conjugate by lysosomal enzymes, and the incorporation of the radionucleoside into DNA.
authors.affiliation: Harvard Medical School, Boston, MA 02115.
authors.forename: S J
authors.initials: SJ
authors.lastname: Adelstein
authors.forename: A I
authors.initials: AI
authors.lastname: Kassis
authors.forename: J
authors.initials: J
authors.lastname: Baranowska-Kortylewicz
authors.forename: A D
authors.initials: AD
authors.lastname: van den Abbeele
authors.forename: G
authors.initials: G
authors.lastname: Mariani
authors.forename: S
authors.initials: S
authors.lastname: Ito
mesh_terms: D006801:Humans; D007065:Idoxuridine / Q000627:therapeutic use*; D007136:Immunoglobulins; D007167:Immunotherapy; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology / Q000532:radiotherapy*
chemical_list: D007136:Immunoglobulins; D007457:Iodine Radioisotopes; D007065:Idoxuridine